Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

EMBO Journal

Volumn 17, Issue 20, 1998, Pages 5896-5904

  Mohammadi, Moosa ^a   Froum, Scott ^a   Hamby, James M ^c   Schroeder, Mel C ^c   Panek, Robert L ^c   Lu, Gina H ^c   Eiiseenkova, Anna V ^a   Green, David ^a   Schlessinger, Joseph ^a,b   Hubbard, Stevan R ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Angiogenesis; Fibroblast growth factor; Tyrosine kinase inhibitor; Vascular endothelial growth factor; X ray crystallography

Indexed keywords

ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HYDROPHOBICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; CELLS, CULTURED; CORNEA; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0032531929     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/17.20.5896     Document Type: Article

References (40)

1. Dumont,D.J., Gradwohl,G., Fong,G.H., Puri,M.C., Gertsenstein,M., Auerbach,A. and Breitman,M.L. (1994) Dominant-negative and targeted null mutations in the endothelial tyrosine kinase, tek, reveal a critical role in vasculogenesis in the embryo. Genes Dev., 8, 1897-1909.
2. Evans,S.V. (1993) SETOR: Hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graphics, 11, 134-138.
3. Folkman,J. and D'Amore,P.A. (1996) Blood vessel formation: what is its molecular basis? Cell, 87, 1153-1155.
4. Fong,G.H., Rossant,J., Gertsenstein,M. and Breitman,M.L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376, 66-70.
5. Fry,D.W., Kraker,A.J., McMichael,A., Ambroso,L.A., Nelson,J.M., Leopold,W.R., Connors,R.W. and Bridges,A.J. (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 265, 1093-1095.
6. Fry,D.W., Nelson,J.M., Slintak,V., Keller,P.R., Rewcastle,G.W., Denny,W.A., Zhou,H. and Bridges,A.J. (1997) Biochemical and antiproliferative properties of 4-[ar (alk)ylamino]pyridopyrimidines. a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol., 54, 877-887.
7. Fujimoto,K., Ichimori,Y., Kakizoe,T., Okajima,E., Sakamoto,H., Sugimura,T. and Terada,M. (1991) Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem. Biophys. Res. Commun., 180, 386-392.
8. Hamby,J.M. et al. (1997) Structure-activity relationships for a novel series of pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem., 40, 2296-2303.
9. Hanahan,D. and Folkman,J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
10. Hubbard,S.R., Wei,L., Ellis,L. and Hendrickson,W.A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature, 372, 746-754.
11. Jaye,M., Schlessinger,J. and Dionne,C.A. (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochem. Biophys. Acta, 1135, 185-199.
12. Johnson,L.N., Noble,M.E.M. and Owen,D.J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell, 85, 149-158.
13. Jones,T.A. (1985) Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. Methods Enzymol., 115, 157-171.
14. Kenyon,B.M., Voest,E.E., Chen,C.C., Flynn,E., Folkman,J. and D'Amato,R.J. (1996) A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci., 37, 1625-1632.
15. Kim,K.J., Li,B., Winer,J., Armanini,M., Gillett,N., Phillips,H.S. and Ferrara,N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
16. Klauber,N., Parangi,S., Flynn,E., Hamel,E. and D'Amato,R.J. (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res., 57, 81-86.
17. Libermann,T.A., Friesel,R., Jaye,M., Lyall,R.M., Westermark,B., Drohan,W., Schmidt,A., Maciag,T. and Schlessinger,J. (1987) An angiogenic growth factor is expressed in human glioma cells. EMBO J., 6, 1627-1632.
18. Martiny-Baron,G., Kazanietz,M.G., Mischak,H., Blumberg,P.M., Kochs,G., Hug,H., Marme,D. and Schachtele,C. (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem., 268, 9194-9197.
19. Millauer,B., Wizigmann-Voos,S., Schnurch,H., Martinez,R., Moller,N.P., Risau,W. and Ullrich,A. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835-846.
20. Millauer,B., Shawver,L.K., Plate,K.H., Risau,W. and Ullrich,A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367, 576-579.
21. Mohammadi,M., Schlessinger,J. and Hubbard,S.R. (1996a) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86, 577-587.
22. Mohammadi,M., Dikic,I., Sorokin,A., Burgess,W.H., Jaye,M. and Schlessinger,J. (1996b) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation snd signal transduction. Mol. Cell. Biol., 16, 977-989.
23. Mohammadi,M., McMahon,G., Sun,L., Tang,C., Hirth,P., Yeh,B.K., Hubbard,S.R. and Schlessinger,J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960.
24. Mustonen,T. and Alitalo,K. (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol., 129, 895-898.
25. Nguyen,M., Watanabe,H., Budson,A.E., Richie,J.P., Hayes,D.F. and Folkman,J. (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst., 86, 356-361.
26. Nicholls,A., Sharp,K.A. and Honig,B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins, 11, 281-296.
27. Otwinowski,Z. (1993) Oscillation data reduction program. In L. Sawyer,L., Isaacs,N. and Burley,S. (eds) Proceedings of the CCP4 Study Weekend. SERC Daresbury Laboratory, Daresbury, United Kingdom, pp. 56-62.
28. Panek,R.L., Lu,G.H., Klutchko,S.R., Batley,B.L., Dahring,T.K., Hamby,J.M., Hallak,H., Doherty,A.M. and Keiser,J.A. (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther., 283, 1433-1444.
29. Partanen,J., Armstrong,E., Makela,T.P., Korhonen,J., Sandberg,M., Renkonen,R., Knuutila,S., Huebner,K. and Alitalo,K. (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol., 12, 1698-1707.
30. Puri,M.C., Rossant,J., Alitalo,K., Bernstein,A. and Partanen,J. (1995) The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J., 14, 5884-5891.
31. Relf,M. et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57, 963-969.
32. Risau,W. (1997) Mechanisms of angiogenesis. Nature, 386, 671-674.
33. Sato,T.N., Tozawa,Y., Deutsch,U., Wolburg-Buchholz,K., Fujiwara,Y., Gendron-Maguire,M., Gridley,T., Wolburg,H., Risau,W., Qin,Y. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 70-74.
34. Shalaby,F., Rossant,J., Yamaguchi,T.P., Gertsenstein,M., Wu,X.F., Breitman,M.L. and Schuh,A.C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376, 62-66.
35. Suri,C., Jones,P.F., Patan,S., Bartunkova,S., Maisonpierre,P.C., Davis,S., Sato,T.N. and Yancopoulos,G.D. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 1171-1180.
36. Taylor,S.S. and Radzio-Andzelm,E. (1994) Three protein kinase structures define a common motif. Structure, 2, 345-355.
37. Trumpp-Kallmeyer,S., Rubin,R.J., Humblet,C., Hamby,J.M. and Showalter,H.D.H. (1998) Development of a binding model to protein tyrosine kinases for substituted pyrido[2, 3-d]pyrimidine inhibitors. J. Med. Chem., 41, 1752-1763.
38. Ullrich,A. and Schlessinger,J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-212.
39. Wang.,Y. and Becker,D. (1997) Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Medicine, 8, 887-893.
40. Yoshiji,H., Harris,S.R. and Thorgeirsson,U.P. (1997) Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res., 57, 3924-3928.